COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,051 Articles (22,627 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 2625: Articles 26241-26250  | Next

Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells
Miersch, S., Ustav, M., Li, Z., Case, J. B., Ganaie, S., Matusali, G., Colavita, F., Lapa, D., Capobianchi, M. R., Novelli, G., Gupta, J. B., Jain, S., Pandolfi, P. P., Diamond, M. S., Amarasinghe, G., Rini, J. M., Sidhu, S. S.
10.1101/2020.06.05.137349 — Posted: 2020-06-06
Human mobility and poverty as key factors in strategies against COVID-19
Yechezkel, M., Weiss, A., Rejwan, I., Shahmoon, E., Ben Gal, S., Yamin, D.
10.1101/2020.06.04.20112417 — Posted: 2020-06-06
Multicenter point-prevalence evaluation of the utilization and safety of drug therapies for COVID-19
Rhodes, N. J., Dairem, A., Moore, W., Shah, A., Postelnick, M. J., Badowski, M. E., Michienzi, S. M., Borkowski, J. L., Polisetty, R. S., Fong, K., Spivek, E. S., Beardsley, J. R., Hale, C. M., Pallotta, A. M., Srinivas, P., Schulz, L. T.
10.1101/2020.06.03.20121558 — Posted: 2020-06-06
Cremation based estimates suggest significant under- and delayed reporting of COVID-19 epidemic data in Wuhan and China
He, M., Li, L., Dehner, L. P., Dunn, L.
10.1101/2020.05.28.20116012 — Posted: 2020-06-06 Discussion: Onsite
Class I HLA allele restricted antigenic coverage for Spike and N proteins is associated with divergent outcomes for COVID-19
Pretti, M. A. M., Galvani, R. G., Vieira, G. F., Bonomo, A., Bonamino, M. H., Boroni, M.
10.1101/2020.06.03.20121301 — Posted: 2020-06-05
Neuropilin-1 is a host factor for SARS-CoV-2 infection
Daly, J. L., Simonetti, B., Anton Plagaro, C., Kavanagh Williamson, M., Shoemark, D. K., Simon-Gracia, L., Klein, K., Bauer, M., Hollandi, R., Greber, U. F., Horvath, P., Sessions, R. B., Helenius, A., Hiscox, J. A., Teesalu, T., Matthews, D. A., Davidson, A. D., Cullen, P. J., Yamauchi, Y.
10.1101/2020.06.05.134114 — Posted: 2020-06-05
A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds
Schoeler, L., Le-Trilling, V. T. K., Eilbrecht, M., Mennerich, D., Anastasiou, O. E., Krawczyk, A., Herrmann, A., Dittmer, U., Trilling, M.
10.1101/2020.06.05.135806 — Posted: 2020-06-05
Dominant and rare SARS-Cov2 variants responsible for the COVID-19 pandemic in Athens, Greece.
Spanakis, N., Kassela, K., Dovrolis, N., Bampali, M., Gatzidou, E., Kafasi, A., Froukala, E., Stavropoulou, A., Lilakos, K., Veletza, S., Tsiodras, S., Tsakris, A., Karakasiliotis, I.
10.1101/2020.06.03.20121236 — Posted: 2020-06-05
Impact of COVID-19 on clinical practice, income, health and lifestyle behavior of Brazilian urologists
Gomes, C. M., Favorito, L., Henriques, J. V. T., Canalini, A. F., Anzolch, K. M. J., Fernandes, R. d. C., Bellucci, C. H. S., Silva, C. S., Wroclawski, M. L., Pompeo, A. C. L., Bessa-Junior, J.
10.1101/2020.06.05.20121566 — Posted: 2020-06-05
Are antibodies tests accurate? Understanding predictive values and uncertainty of serology tests for the novel coronavirus.
Brownstein, N. C., Chen, Y. A.
10.1101/2020.06.04.20122358 — Posted: 2020-06-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).